Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 966
- Registration Number
- NCT00003026
- Locations
- 🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇳🇱Academisch Ziekenhuis Groningen, Groningen, Netherlands
🇬🇧City General Hospital, Stoke-On-Trent, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.